Chemomab Therapeutics Ltd. (id:6392 CMMB)
1.71 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 10:57:31 AM)
Exchange open, closes in 5 hours 2 minutes
1.96 USD (1.96%)
3.19 USD (3.19%)
-2.11 USD (-2.11%)
87.62 USD (87.62%)
235.88 USD (235.88%)
-92.46 USD (-92.46%)
-99.07 USD (-99.07%)
About Chemomab Therapeutics Ltd.
Market Capitalization 31.87M
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
| Headquarters (address) |
Building 7 Tel Aviv 6158002 Israel |
| Phone | 972 77 331 0156 |
| Website | https://www.chemomab.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CMMB |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.00 - 2.55 |
| Market Capitalization | 31.87M |
| P/E trailing | 3.00 |
| P/E forward | -42.25 |
| Price/Book | 1.41 |
| Beta | 3.00 |
| EPS | 3.00 |
| EPS Israel (ID:92, base:52) | 3.00 |